Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma

NCT02465268 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT02465268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02465268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2016
Completion date
November 30, 2023
Enrollment
175 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iv, gbm, glioblastoma, glioblastoma multiforme, malignant glioma